NCT05830539View on ClinicalTrials.gov

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

November 22, 2024

Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
DRUG

IN10018+PLD

IN10018 orally once daily; PLD 40mg/m2, Q4W

DRUG

IN10018+PLD+Toripalimab

IN10018 orally once daily; PLD 40mg/m2, Q4W; Toripalimab 3 mg/kg, Q2W

Trial Locations (7)

Unknown

Anyang Tumor Hospital, Anyang

Henan Cancer Hospital, Zhengzhou

Henan Provincial People's Hospital, Zhengzhou

Hubei Cancer Hospital, Wuhan

Hunan Cancer Hospital, Changsha

The Third Hospital of Nanchang, Nanchang

Obstetrics & Gynecology Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

InxMed (Shanghai) Co., Ltd.

INDUSTRY

NCT05830539 - IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients | Biotech Hunter | Biotech Hunter